UT NanoMedicine Director Named AIMBE Fellow
HOUSTON – (Oct. 17, 2008)– Mauro Ferrari, Ph.D., professor and director of the Division of NanoMedicine at The University of Texas Health Science Center at Houston, has been elected to the College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE).
Mauro Ferrari, Ph.D.
“We are delighted that Dr. Ferrari’s visionary work in the fields of nanomedicine and biomedical engineering has been recognized by his colleagues with this prestigious award,” said Peter Davies, M.D., Ph.D., the university’s executive vice president of research.
Ferrari, deputy chairman of the Department of Biomedical Engineering, a joint venture between the UT Health Science Center at Houston, The University of Texas at Austin and The University of Texas M. D. Anderson Cancer Center, is the first faculty member from the UT Health Science Center to be elected to AIMBE’s College of Fellows. He joins almost 1,000 other fellows who are bioengineering leaders in academia, industry and government and have distinguished themselves through their contributions to research, industrial practice and/or education.
AIMBE was established in 1991 as a leading advocacy group for medical and biological engineering. Its goal is to promote awareness of the field and its contributions to society in terms of new technologies that improve medical care and produce more and higher-quality food for people throughout the world. The institute also works with lawmakers, government agencies and other professional groups to promote public policies that further advancements in the field.
Research in Ferrari’s laboratory is directed at the early detection of disease from biological fluids, the autonomous (time-controlled and spatially directed) delivery of therapeutics agents, the continuous monitoring of disease progression, and the real-time evaluation of the efficacy of therapeutic intervention. Completed work demonstrates how silicon-based implants can be engineered to provide long-term therapeutic delivery for treatment of chronic and acute conditions. His laboratory has also pioneered the development of proteomic nanodevices for analysis of low-concentration biomarkers in biological fluids.
In addition to his UT Health Science Center at Houston appointments, Ferrari is professor of experimental therapeutics at The University of Texas M. D. Anderson Cancer Center, professor of bioengineering at Rice University and president of the Houston-based Alliance for NanoHealth consortium.
For information, visit www.aimbe.org.